JP2022546424A5 - - Google Patents

Info

Publication number
JP2022546424A5
JP2022546424A5 JP2022513209A JP2022513209A JP2022546424A5 JP 2022546424 A5 JP2022546424 A5 JP 2022546424A5 JP 2022513209 A JP2022513209 A JP 2022513209A JP 2022513209 A JP2022513209 A JP 2022513209A JP 2022546424 A5 JP2022546424 A5 JP 2022546424A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
virus
influenza
inhibitor
cap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546424A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/073934 external-priority patent/WO2021037956A1/en
Publication of JP2022546424A publication Critical patent/JP2022546424A/ja
Publication of JP2022546424A5 publication Critical patent/JP2022546424A5/ja
Pending legal-status Critical Current

Links

JP2022513209A 2019-08-27 2020-08-27 Mek阻害剤とキャップ依存性エンドヌクレアーゼ阻害剤との組み合わせ Pending JP2022546424A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LU101372 2019-08-27
LULU101372 2019-08-27
PCT/EP2020/073934 WO2021037956A1 (en) 2019-08-27 2020-08-27 Combinations of mek inhibitors with cap-dependent endonuclease inhibitors

Publications (2)

Publication Number Publication Date
JP2022546424A JP2022546424A (ja) 2022-11-04
JP2022546424A5 true JP2022546424A5 (cg-RX-API-DMAC7.html) 2023-09-01

Family

ID=68234302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513209A Pending JP2022546424A (ja) 2019-08-27 2020-08-27 Mek阻害剤とキャップ依存性エンドヌクレアーゼ阻害剤との組み合わせ

Country Status (10)

Country Link
US (1) US20220370384A1 (cg-RX-API-DMAC7.html)
EP (1) EP4021435A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022546424A (cg-RX-API-DMAC7.html)
KR (1) KR20220074869A (cg-RX-API-DMAC7.html)
CN (1) CN114667138A (cg-RX-API-DMAC7.html)
AU (1) AU2020338695A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022003673A2 (cg-RX-API-DMAC7.html)
CA (1) CA3149588A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022002413A (cg-RX-API-DMAC7.html)
WO (1) WO2021037956A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
CN115151533B (zh) 2020-01-10 2025-08-08 医疗免疫工程公司 Mek抑制剂及其治疗用途
WO2024042050A1 (en) * 2022-08-22 2024-02-29 Atriva Therapeutics Gmbh Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10017480A1 (de) * 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
LT2620436T (lt) * 2010-09-24 2018-08-10 Shionogi & Co., Ltd. Pakeistojo policiklinio karbamoilpiridono darinio provaistas
CN109276716B (zh) 2012-10-08 2021-06-08 归属疗法有限公司 用在病毒性疾病的治疗中的mek抑制剂
EP3142658B1 (en) * 2014-05-16 2020-01-15 Atriva Therapeutics GmbH Novel anti-infective strategy against influenza virus and s. aureus coinfections
US10759814B2 (en) * 2016-08-10 2020-09-01 Shionogi & Co., Ltd. Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
SI3697405T1 (sl) 2017-10-17 2021-11-30 Atriva Therapeutics Gmbh Novi zaviralec MEK za zdravljenje virusnih in bakterijskih okužb
US20190298669A1 (en) * 2018-03-29 2019-10-03 Atriva Therapeutics Gmbh Ci-1040 for the treatment of viral diseases

Similar Documents

Publication Publication Date Title
JP2015534562A5 (cg-RX-API-DMAC7.html)
CN114786659B (zh) 用于治疗汉坦病毒感染的mek抑制剂
JP2022551458A5 (cg-RX-API-DMAC7.html)
JP2018021051A5 (cg-RX-API-DMAC7.html)
JP2020537659A5 (cg-RX-API-DMAC7.html)
JP2019509276A5 (cg-RX-API-DMAC7.html)
US20220125767A1 (en) Thiazolide compounds for treating viral infections
MX2022003984A (es) Compuestos heterociclicos antivirales.
JP2017525681A (ja) パラミクソウイルスの治療方法
JP2025508656A5 (cg-RX-API-DMAC7.html)
JP2013209405A5 (cg-RX-API-DMAC7.html)
UY40215A (es) Compuestos heterocíclicos antivirales
JP2023520323A5 (cg-RX-API-DMAC7.html)
JP2020529995A5 (cg-RX-API-DMAC7.html)
JP2025124703A (ja) ウイルス感染および細菌感染の治療のための新規mek阻害剤
WO2021195521A1 (en) Methods of treating coronavirus infections
CL2024001073A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
WO2022013324A3 (en) Post-exposure vaccination against viral respiratory infections
JP2022546424A (ja) Mek阻害剤とキャップ依存性エンドヌクレアーゼ阻害剤との組み合わせ
JP2022505183A5 (cg-RX-API-DMAC7.html)
JP2008088189A5 (cg-RX-API-DMAC7.html)
EP3934653A1 (en) Azelastine as antiviral treatment
JPWO2021221111A5 (cg-RX-API-DMAC7.html)
JP2013542262A5 (cg-RX-API-DMAC7.html)
CA3152450C (en) Mek inhibitors for the treatment of hantavirus infections